- Home
- Equipment
- north america
- t cells
Show results for
Refine by
Applications
- 3D bioprinting technology for breast disease
- 3D bioprinting technology for lung disease
- 3D bioprinting technology for brain disease
- 3D bioprinting technology for liver disease
- 3D bioprinting technology for skin disease
- 3D bioprinting technology for pancreas disease
- 3D bioprinting technology for prostate disease
- Solution for Clinical Trials
- Solution for Access to Investigational Medicines
- Software Solutions for Deep Mutational Scanning & Selection
- Software Solutions for COVID-19
T Cells Equipment Supplied In North America
449 equipment items found
Manufactured by:Trailhead Biosystems Inc. based inBeachwood, OHIO (USA)
We are developing cell culture media for T-cell subtype control to improve clinical potency in the individual patient and reduction of variability in outcomes between patients. CAR T-cell therapy involves the treatment of cancer by modifying a patient’s T-cells in the lab ...
by:Vir Biotechnology, Inc. based inSan Francisco, CALIFORNIA (USA)
We are exploiting the unique immunology of human cytomegalovirus, or HCMV, a commonly occurring virus in humans, as a delivery vehicle – or vector – for vaccines to potentially treat and prevent infection by pathogens that are refractory to current vaccine technologies. HCMV is the most potent known inducer of T cell responses of any human virus and ...
Manufactured by:Sana Biotechnology based inSeattle, WASHINGTON (USA)
Oncology: Multiple ...
Manufactured by:Sana Biotechnology based inSeattle, WASHINGTON (USA)
Oncology: Multiple ...
Manufactured by:Adaptimmune LLC based inPhiladelphia, PENNSYLVANIA (USA)
Our ADP-A2M4 (MAGE-A4) SPEAR T-cell therapy is directed to a member of the MAGE family of cancer testis antigen expressed in a number of solid tumor cell types. The MAGE- A4 antigen is among the most commonly expressed cancer-testis antigens. We are conducting various trials with the ADP-A2M4 SPEAR T-cell in ...
Manufactured by:Adaptimmune LLC based inPhiladelphia, PENNSYLVANIA (USA)
Our ADP-A2M10 (MAGE-A10) T-cell therapy is directed to a member of the MAGE family of cancer testis antigens expressed in a number of solid tumor cell types. Any expression in cancer is often associated with higher grade tumors. Please note that the two trials with ADP-A2M10 are now closed for ...
Manufactured by:T-Cure BioScience, Inc. based inSherman Oaks, CALIFORNIA (USA)
T cell engineering with TCRs is a growing area of immuno-oncology with recent breakthroughs in clinical settings. The T-Cure approach involves identifying and isolating a high avidity TCR which specifically recognizes an intracellular or cell-surface target in solid tumors. This TCR is then typically introduced into a viral ...
Manufactured by:Adaptimmune LLC based inPhiladelphia, PENNSYLVANIA (USA)
Our ADP-A2M4CD8 SPEAR T-cell therapy is our first "next-generation" therapy and is directed to MAGE-A4, a member of the MAGE family of cancer-testis antigens expressed in a number of solid tumor types. What differentiates this therapy from our ADP-A2M4 SPEAR T-cells is that these cells also express the CD8α ...
Manufactured by:IN8Bio Inc. based inNew York, NEW YORK (USA)
INB-300, our DeltEx DRI CAR-T, is a preclinical product candidate combining our expertise in gamma-delta T cells, our DRI technology and a novel CAR-directed against the Cholotoxin peptide. Chlorotoxin binds to GBM tumor cells and has been previously utilized as a tumor paint in this setting. ...
Manufactured by:LAVA Therapeutics N.V. based inUtrecht, NETHERLANDS
Vγ9Vδ2 T cells belong to the first line of defense against cancer and have the potential to elicit deep and durable responses in the ...
Manufactured by:IN8Bio Inc. based inNew York, NEW YORK (USA)
Our DeltEx platform has enabled a deep pipeline of preclinical and clinical product candidates, which are designed to effectively target and potentially eradicate disease, to improve patient ...
Manufactured by:Adicet Bio based inMenlo Park, CALIFORNIA (USA)
Gamma delta T cells represent a new generation of universal cell therapy. The current engineered autologous alpha beta T cell products have shown significant efficacy in hematological malignancies; however comparable efficacy in solid tumors is yet to be proven. The cell platform and novel ...
Manufactured by:Sana Biotechnology based inSeattle, WASHINGTON (USA)
Oncology: Non-Hodgkin lymphoma (NHL), Acute lymphoblastic leukemia (ALL), Chronic lymphocytic leukemia ...
Manufactured by:Sana Biotechnology based inSeattle, WASHINGTON (USA)
Oncology: Non-Hodgkin lymphoma (NHL), Acute lymphoblastic leukemia (ALL), Chronic lymphocytic leukemia ...
Manufactured by:Adaptimmune LLC based inPhiladelphia, PENNSYLVANIA (USA)
Our ADP-A2AFP SPEAR T-cell product targets alpha-fetoprotein (AFP) is being investigated in an ongoing Phase 1 clinical trial for the treatment of patients with hepatocellular carcinoma (liver ...
Manufactured by:Takeda Pharmaceutical Company Limited based inChuo-ku, JAPAN
Adaptate Biotherapeutics is focussed on therapeutic antibodies which harness the potential of patients’ own gamma delta T cells in situ. Gamma delta T cells play a critical role in immune surveillance, recognising malignant/transformed cells through a pattern of stress markers and exerting potent ...
Manufactured by:Fate Therapeutics, Inc. based inSan Diego, CALIFORNIA (USA)
CAR T-cell therapy has recently emerged as a revolutionary and potentially curative therapy for patients with certain hematologic malignancies, including refractory cancers. In 2017, two CAR T-cell therapies were approved by the FDA for the treatment of relapsed / refractory B-cell precursor acute lymphoblastic ...
Manufactured by:Adaptimmune LLC based inPhiladelphia, PENNSYLVANIA (USA)
Our goal is to revolutionize cancer therapy on a global basis by developing TCR T-cell therapies (called SPEAR T-cells) with the potential to treat a wide range of cancer types and patients. Our TCR T-cell therapies have advantages over other immune therapies and cancer therapies. The video below ...
by:Sorrento Therapeutics, Inc. based inSan Diego, CALIFORNIA (USA)
Sorrento utilizes a proprietary knock-out knock-in (KOKI) technology to modify normal healthy donor derived T cells to genetically engineer them to express the dimeric antigen receptor into T-cell receptor (TCR) alpha chain constant region (TRAC). In this manner, TRAC is knocked out and antigen is knocked into its locus. ...
by:Ab Studio Inc. based inHayward, CALIFORNIA (USA)
Bispecific antibodies with computationally optimized differential binding affinities, biochemical and biophysical features, and a common light ...